Health Care·Biotechnology·$5.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.84 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.84 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach, emphasizing the importance of their current projects. They did not provide any updates on future guidance.
Management did not provide specific guidance for the upcoming quarters.
The company is focused on its ongoing projects and strategic initiatives.
The earnings report indicates that Rhythm Pharmaceuticals is still facing challenges, particularly reflected in their EPS results. The stock's slight decline of 0.97% suggests that investors may be reacting to the lack of revenue data and guidance. Without clear direction from management, uncertainty remains about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BIO-TECHNE CORP
Apr 30, 2019